

12 April 2021

**Diaceutics PLC**  
**("Diaceutics" or "the Company")**

**New Vice President of Operations within the Asia Pacific region**  
*Appointment for Asia Pacific region to expand Diaceutics portfolio*

[Diaceutics PLC](#), (AIM: DXRX), announces the appointment of Yvanka Gilliam as Vice President for the Asia Pacific region (APAC).

In her new role, Yvanka will be responsible for managing business development and operations within the APAC region with a core focus on establishing key collaborations and strategic partnerships to drive growth and revenue. Her role will also include identifying innovative and creative services and solutions to help leverage the Company's platform DXRX and increase the offering.

Yvanka has a strong track record managing the delivery of real-world insights for evaluation by regulators, payers and clinicians. Prior to joining Diaceutics, Yvanka worked with Kantar Health as a Senior Client Partner, Real World Evidence, where she developed and implemented global business planning strategies and conducted high-quality research. In recent years, Yvanka has also worked with IQVIA Asia Pacific in the Real World Insights Division and as a Senior Medical Science Liaison at AstraZeneca Pharmaceutical Corporation.

Yvanka holds a doctorate degree in Pharmacy from The University of Michigan College of Pharmacy in Ann Arbor, a bachelor's degree in Biology and Chemistry from Grambling University in Louisiana and an MBA in International Business from Rutgers University Singapore. Yvanka's work has been [published](#) in the Annals of Oncology and the [Journal](#) of Clinical Oncology - an American Society of Clinical Oncology (ASCO) Journal.

**Peter Keeling, Chief Executive Officer of Diaceutics, said:** *"Yvanka's appointment will strengthen Diaceutics' credentials as the market leader in the development and commercialisation of precision medicine diagnostics. As her 20-plus year career in pharma has been focused primarily on the Research and Development of innovative oncology compounds, Yvanka is firmly aligned with Diaceutics' goal to bridge the gap between diagnostics and therapeutic decision-making in order to improve testing outcomes for patients and enable better access to the right drug at the right time."*

**Yvanka Gilliam, Diaceutics VP of Operations, APAC, said:** *"I'm delighted to join Diaceutics, a Company that I have long admired for their unwavering commitment to drive better testing and better treatment for patients. I look forward to broadening Diaceutics' influence in the APAC region and working alongside a team of driven and talented individuals. I'm particularly excited to come on board as the Company's DXRX - The Diagnostic Network® platform continues to gain traction within the industry, as we help get every patient the treatment they deserve."*

**About RNS REACH**

This is an RNS Reach announcement and the information contained is not considered to be material or to have a significant impact on management's expectations of the Group's performance. RNS Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

**Enquiries:**

**Diaceutics PLC**

Philip White, Chief Financial Officer

Via Walbrook PR

**Centkos Securities plc (Nomad & Broker)**

Callum Davidson / Giles Balleny  
Michael Johnson (Sales)

Tel: +44(0)20 7397 8900

**Walbrook PR**

Anna Dunphy  
Paul McManus

Tel: +44 (0)20 7933 8780 or [diaceutics@walbrookpr.com](mailto:diaceutics@walbrookpr.com)

Tel: +44 (0)7876 741 001  
Tel: +44 (0)7980 541 893

**About Diaceutics**

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - our Proprietary Diagnostic Network solution for the development and commercialisation of

precision medicine diagnostics. Diaceutics has worked on every precision medicine brought to market and provides solutions to 36 of the world's leading pharmaceutical companies. DXRX - The Diagnostic Network® provides unrivalled access to deep analysis and insights from the world's largest repository of diagnostic testing data on one secure platform.

**About DXRX - The Diagnostic Network®**

DXRX is Diaceutics' proprietary diagnostic network for precision medicine. DXRX is an end-to-end solution for the development and commercialisation of Precision Medicine diagnostics. The platform enables a vibrant marketplace where all stakeholders in Precision Medicine come to find trusted partners and collaborations in a secure, standardised way. DXRX provides access to a pipeline of global diagnostic testing data on one secure platform.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRAFLFERSVIAAIL